Evidence map›Paper›PMID 42278489›Full record

ArticleInternational journal of molecular sciences2026

CCR5+ CD8+ T Cells Are Associated with Poor Response to PD-1 Blockade Therapy.

Ziheng Zhao, Yuwei Liu, Zhaofei Wu, Chunliang Qi, Yingze Ning, Yiting Lin, Xuewen Pang, Guangliang Qiang, Wei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ziheng ZhaoNHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China.
Yuwei LiuNHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China.
Zhaofei WuNHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China.ORCID 0000-0003-3385-6449
Chunliang QiNHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China.
Yingze NingDepartment of Thoracic Surgery, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China.
Yiting LinNHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China.
Xuewen PangNHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China.
Guangliang QiangDepartment of Thoracic Surgery, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China.ORCID 0000-0002-7809-1892
Wei WangNHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China.

Funding

Beijing Natural Science Foundation L234020Beijing Natural Science Foundation L244064China Postdoctoral Science Foundation 2023TQ0016China Postdoctoral Science Foundation GZC20230135National Natural Science Foundation of China 32470966
6 · The paper itself

Abstract

Many patients develop poor clinical response to immune checkpoint inhibitors (ICIs), especially PD-1/PD-L1 blockade. However, transcriptomic features of chemokine receptors associated with poor response remain incompletely characterized. We analyzed publicly available single-cell RNA sequencing datasets from non-small-cell lung cancer (NSCLC) and melanoma cohorts, with additional exploratory analyses in hepatocellular carcinoma (HCC) and colorectal cancer datasets. Chemokine receptor expression on CD8+ T cells from clinical responsive and non-responsive samples to anti-PD-1 therapy was systematically profiled. Differential gene expression, cell-state scoring, pseudotime trajectory inference, and ligand-receptor interaction analysis were performed to characterize associated transcriptional states and predicted cellular interactions.

Indexed as

CD8-Positive T-LymphocytesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorReceptors, CCR5T-Cell ExhaustionB7-H1 AntigenCarcinoma, HepatocellularCarcinoma, Non-Small-Cell LungChemokine CCL3Chemokine CCL4Colorectal NeoplasmsGene Expression Regulation, NeoplasticHumansLiver NeoplasmsLung NeoplasmsLymphocytes, Tumor-InfiltratingB7-H1 AntigenCCL4 protein, humanCCR5 protein, humanChemokine CCL3Chemokine CCL4Immune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, CCR5CCR5CD8+ T cellsexhaustionPD-1 blockade therapy

Identifiers

PMID42278489
PMCPMC13256934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.